The recent identification of reliable adult stem cell markers in the intestine has driven major advances in our understanding of stem cell roles in both normal tissue homeostasis and cancer. A principal route to colon cancer initiation is aberrant activation of Wnt signalling activity in long-lived adult stem cells at the crypt base. Tumour-resident stem cell populations within the resulting adenomas are considered likely targets for accumulation of additional mutations, driving a stepwise transition towards invasive carcinoma. These purported cancer stem cell populations have received widespread interest as potential therapeutic targets, fuelling efforts to identify specific biomarkers that facilitate their isolation and/or the development of tailored drugs. Here we review recent advances in (cancer) stem cell biology and highlight the obstacles to translation of this knowledge into therapeutic applications in the clinic.
Share this Article
Related Content In Stem Cell Transplantation
Bmi1 – A Path to Targeting Cancer Stem Cells
European Oncology & Haematology, 2017;13(2):147–51 DOI: https://doi.org/10.17925/EOH.2017.13.02.147
Since the discovery of the Polycomb group (PcG) gene family in Drosophila as repressors of homeotic (HOX) genes, PcG proteins have been implicated in a range of processes from chromosome X inactivation to stem cell plasticity and differentiation. PcG proteins execute their function through transcriptional repression of the promoter region of a target gene. Although […]
Plasmacytic Post-transplant Lymphoproliferative Disorder – Case Report
European Oncology & Haematology, 2017;13(1):80–2 DOI: https://doi.org/10.17925/EOH.2017.13.01.80
Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT). Most of the PTLDs originate from B-cells. Overall, 60–80% of PTLDs are associated with Epstein-Barr virus (EBV); this can vary depending on PTLD type and time of onset after HSCT.1,2 The majority of the general population is infected by EBV during their […]
Targeting Cancer Stem Cells—A Renewed Therapeutic Paradigm
Oncology & Hematology Review, 2017;13(1):45–55 DOI: https://doi.org/10.17925/OHR.2017.13.01.45
Despite substantial advances in cancer diagnosis and treatment, the long-term survival rate for many cancer patients remains dismal.1 More than 90% of cancer-related mortality is ascribed to disease resurgence months or years after adjuvant therapy, either in the form of local recurrence or in the form of metastatic spread, which are typically refractory to existing […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!